A semi-synthetic flavanone derivative showcasing powerful antioxidant potential and precision chemistry developed by Advent’s R&D team.
Mumbai, India – November 2025: Advent, a leading name in the field of pharmaceutical impurities and working standards, has announced the launch of its latest innovation under its signature Molecule of the Month campaign — Flavanone Diacetyl Hydrazone (FDH). Developed and characterized entirely in-house by the Advent R&D team, FDH represents another step forward in the company’s mission to support advanced scientific research with precision-engineered reference materials.
FDH (N-acetyl-N′-(2-phenyl-2,3-dihydro-4H-chromen-4-ylidene)acetohydrazide) is a semi-synthetic derivative of the flavanone scaffold, designed to explore the intricate relationship between oxidation, inflammation, and cellular protection. With a purity of over 98% and successful mg-to-g scalability, this compound underscores Advent’s technical capability in delivering high-quality materials suitable for global pharmaceutical and biomedical research.
“At Advent, every molecule we create tells a story of scientific curiosity and precision,” said Nitin Patil, Head of Research & Development at Advent. “Flavanone Diacetyl Hydrazone exemplifies our team’s ability to merge synthetic innovation with analytical excellence. It’s not just a molecule—it’s a tool for discovery.”
An Innovation Rooted in Research
FDH belongs to a class of flavanone–hydrazone hybrids that have shown promise in antioxidant and anti-inflammatory studies. Its unique structural configuration enables hydrogen donation to neutralize reactive oxygen species, making it a valuable probe for redox biology research.
While research into flavanone hydrazones continues to expand globally, Advent’s FDH brings reliability, reproducibility, and analytical clarity to the forefront. The molecule has been comprehensively characterized using ¹H NMR, Mass, IR, and TGA—ensuring confidence for scientists studying oxidative stress pathways, inflammation modulation, and molecular stability.
Setting New Standards in Molecule Development
With the introduction of FDH, Advent Chembio continues to reinforce its commitment to bridging discovery and application through meticulous chemistry and characterization.
The company’s Molecule of the Month campaign, launched in 2024, celebrates innovative molecules that showcase the team’s expertise in synthetic development, scale-up, and quality validation. Each monthly feature highlights compounds that push the boundaries of pharmaceutical research while maintaining Advent’s uncompromising focus on data integrity and analytical transparency.
“Our goal is to inspire curiosity within the scientific community,” said Dr. Rashmi Ranjan Mohanty, Director- Technical at Advent Chembio. “The Molecule of the Month initiative not only showcases our R&D excellence but also underscores our role as an innovation partner for pharma and research organizations around the world.”
About Advent
Advent Chembio Pvt. Ltd. is a trusted manufacturer of pharmaceutical impurities, reference standards, and working standards, catering to leading pharmaceutical companies and research institutions across India and overseas.
With a strong focus on quality, scalability, and scientific collaboration, Advent’s in-house R&D and analytical teams consistently deliver compounds that meet the most demanding global standards.
From milligram to gram scale, Advent ensures each molecule is developed with precision, purity, and purpose—empowering researchers to pursue breakthroughs with confidence.